Considering the mechanistic overlap in the development and progression of CKD in type 1 and type 2 diabetes, there exists a strong rationale for simultaneously developing novel CKD therapies for use in both type 1 diabetes and type 2 diabetes and studying the repurposing of existing type 2 diabetes CKD therapies for the treatment of CKD in people with type 1 diabetes
Jiang T, Cheng H, Su J, Wang X, Wang Q, Chu J, et al
Areas covered The clinical and genetic characteristics of different PFIC and AOCD are summarized to provide a common background for geneticists and paediatric and adult hepatologists in diagnosis and management
Supernatants were removed, diluted 1:1 with 2% acetonitrile in 0.1% formic acid (water), filtered, and analyzed by HPLC-MS/MS
Consult an appropriate healthcare professional before using a new supplement, particularly when pregnant, nursing, immunocompromised, taking medication or managing diabetes or another medical condition
Scorpion venomics: a 2019 overview